Our main interest is to understand how tumor cells respond to cancer therapy. We explore molecular mechanisms behind cancer pathogenesis and therapy response, and search for biomarkers, which could be used as prognostic and/or predictive factors for treatment and survival. Furthermore, we perform clinical trials based on the generated translational data. Our cancer model is lymphoma.
Read more
@LeppaSM

Just published! We proudly present "Hallmarks of Cancer: New Dimensions" by Douglas Hanahan, the third update to th… twitter.com/i/web/status/1…

iCAN sai Suomen Akatemialta 14 miljoonan euron jatkorahoituksen – jatkamme työtämme yksilöllisten syöpähoitojen edi… twitter.com/i/web/status/1…

These sobering results make me wonder if #ACIP #CDC should recommend revaccinating lymphoma pts with full primary s… twitter.com/i/web/status/1…

Recent Publications

RSS Feed

No results.